HLA antibody detection with single antigen flow beads (SAFB) assays is impaired by complement interference whose frequency, predictability and distribution among HLA antigens have not been analyzed in large cohorts. We compared in two patients' cohorts the routine follow-up SAFB profiles obtained in class I (n = 129) and class II (n = 85) with and without ethylenediaminetetraacetic acid (EDTA)-treatment. The presence of complement interference was defined according to the reproducibility of the SAFB assays evaluated with our class I and II routine positive control sera. Interference occurred in 29.5% and 45.9% of patients in class I and II, respectively. In the untreated condition, at serum level, neither the number of positive beads, the highest bead mean fluorescence intensity (MFI) nor MFI at bead level, satisfactorily predicted interference. HLA-C were the least affected among class I beads. HLA-DQ beads were the most affected in class II. At least one antibody specificity was falsely negative without EDTA for about 3% of sera in class I and 9% in class II. EDTA-treatment did not significantly modify the low-MFI strengths (500-3000 range). This study emphasizes the high frequency of complement interference and the importance and advantages of systematically pretreating sera with EDTA before performing SAFB assays.
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| INTRODUCTION
Because their release for anti-HLA IgG characterization, the single antigen flow beads assays (SAFB) have greatly improved the allocation of solid organ transplants and the organ recipients' follow-up. However, the SAFB are not devoid of limitations such as drugs interference, 1 falsepositive 2-4 and more troublesome false-negative results. The first evoked negative interference was caused by anti-HLA IgM competing with IgG for the antigen. Treatment of sera with dithiothreitol (DTT) or hypotonic dialysis significantly increased IgG mean fluorescence intensity (MFI) of numerous reactivities detected in sera also containing anti-HLA IgM. [5] [6] [7] Schnaidt et al. published a seminal paper describing the "prozone effect" for high-MFI anti-HLA IgG that was reversed by the DTT, ethylenediaminetetraacetic acid (EDTA), heating or serum dilution. 8 The mechanism of this interference was elucidated by Schwaiger et al. 9 and our group. 10 It is caused by a steric hindrance at the bead surface, mainly because of the covalent binding and accumulation of C4 and C3 degradation products over the immune Gwendaline Guidicelli and Jonathan Visentin contributed equally to this study.
Abbreviations: DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid; MFI, mean fluorescence intensity; ROC, receiver operating characteristics; SAFB, single antigen flow beads; SD, standard deviation complexes, rendering them less or not accessible to the fluorescent anti-IgG conjugate. Noteworthy, we showed that at least a part of the interference because of anti-HLA IgM for IgG detection was also caused by complement activation. 7, 11 Complement interference has a very important clinical impact. It is responsible for important fluctuations during patients' follow-up 12, 13 and has led to the ignorance or underestimation of strong IgG anti-HLA antibodies in recipients having obvious humoral rejections or positive complementdependent cytotoxicity crossmatches (unpublished results). In order to remove this interference, we implemented into the routine a systematic serum EDTA pretreatment at the end of year 2012. Yet, several questions about this interference remain unanswered, especially regarding the possibility to anticipate its occurrence from untreated serum MFI levels, its prevalence and amplitude in the patients' population, and its distribution among HLA antigens. Finally EDTA treatment, while widely used, was not proven innocuous for authentic low-MFI antibodies on a large scale. 14 We aimed to answer these questions in two cohorts by comparing, in class I and class II, the SAFB profiles obtained with the same sera tested with and without EDTA.
| MATERIAL AND METHODS

| Sera and anti-HLA antibody assays
The cohorts contained all the sera analyzed over 1 month in our laboratory, drawn from patients in the pre-or post-organ transplant setting. The class I and class II SAFB assay kits were from One Lambda (Canoga Park, CA 
| Definition of the presence of complement interference
We defined complement interference according to the results from the two class I and the unique class II routine positive control sera used at the time of this study. The first class I control was used for 13 routine batches and provided mean normalized MFI between 258 and 9264, the second one was used for 11 batches and provided mean MFI between 978 and 17 455. The class II control was used for 18 batches and provided mean MFI between 2590 and 20 498. We calculated the SD for each individual class I or II bead (n = 283, for the three controls) displaying a mean MFI ≥ 500 with at least one of these three controls. Next, for each bead, three SD were subtracted from the corresponding mean MFI to obtain the "mean-3SD" value. The 283 "mean-3SD" values were then plotted against their mean MFI and a linear regression generated the equation that defined, for any given MFI obtained with EDTA, the threshold below which the MFI without EDTA indicated the presence of the interference.
| Statistical analysis
Descriptive statistics used median and fifth to 95th percentiles or first and third quartiles, when appropriate. 3 | RESULTS
| Prevalence of complement interference in SAFB assays
We analyzed the prevalence of complement interference in two class I and II cohorts with respectively 129 and 85 sera tested in parallel with and without EDTA with the same SAFB lot, from as many patients. Among the 12 513 and 7486 class I and II beads tested, respectively 5177 (41.4%) and 2317 (31.0%) were positive in the EDTA-treated serum. The MFI of these beads was lower in the untreated serum (Table 1 , P < .0001). A total of 288 (5.6%) and 290 (12.5%) class I and II beads, respectively, suffered from complement interference for the serum of 38 (29.5%) and 39 (45.9%) patients tested (Figure 1 ).
| Prediction of complement interference
We aimed to determine whether complement interference could be predicted from the number of positive beads and the highest bead MFI for a given serum tested without EDTA, and from the MFI obtained without EDTA for any positive bead. For class I, at patient level, the number of positive beads provided a modest ROC AUC for predicting complement interference (0.758, P < .0001) with an optimal beads number of 44 providing 71.1% sensitivity, 65.9% specificity, 2.09 and 0.44 positive and negative likelihood ratios, respectively. The highest bead MFI provided a ROC AUC of 0.656 (P = .001) with an optimal MFI of 11 419 providing 92.1% sensitivity, 49.5% specificity, 1.82 and 0.16 positive and negative likelihood ratios, respectively. At bead level, the ROC analysis led to a modest AUC (0.683, P < .0001) with an optimal MFI of 3440, 85.2% sensitivity, 47.8% specificity, 1.63 and 0.31 positive and negative likelihood ratios, respectively. As a comparison, the same analysis at bead level after EDTA treatment provided a very good AUC (0.935, P < .0001), an optimal MFI of 13 266, 89.2% sensitivity, 86.5% specificity, 6.62 and 0.12 positive and negative likelihood ratios, respectively. Similar results were obtained for class II. At patient level, the number of positive beads provided a ROC AUC for predicting complement interference of 0.643 (P = .018) with an optimal beads number of 23 providing 70.0% sensitivity, 55.8% specificity, 1.66 and 0.52 positive and negative likelihood ratios, respectively. The highest bead MFI provided a ROC AUC of 0.764 (P < .0001) with an optimal MFI of 7589 providing 92.5% sensitivity, 57.8% specificity, 2.19 and 0.13 positive and negative likelihood ratios, respectively. At bead level, the ROC analysis led to a modest AUC (0.691, P < .0001) with an optimal MFI of 4656, 74.0% sensitivity, 61.1% specificity, 1.90 and 0.42 positive and negative likelihood ratios, respectively. As a comparison, the same analysis at bead level after EDTA treatment provided a very good AUC (0.918, P < .0001), an optimal MFI of 11 142, 90.0% sensitivity, 80.3% specificity, 4.57 and 0.12 positive and negative likelihood ratios, respectively.
| Distribution and amplitude of complement interference
In class I, among the 38 sera showing interference, the median number of affected beads per serum was four (minimum 1, maximum 48, first quartile 2 and third quartile 10). Among them, 27 (71.1%) suffered interference on HLA-A beads, 21 (55.3%) on HLA-B and 6 (15.8%) on HLA-C. Noteworthy, 4 sera (10.5% of the sera displaying complement interference and 3.1% of the total number of sera) had at least one antibody specificity with a MFI incorrectly measured <500 and as such considered as absent. The distribution and the amplitude of the interference for each class I locus are shown in Table 2 , Figure 2A and SDC, Figure S1A in Appendix S1, Supporting Information, and for the class I alleles in SDC, Table S1 in Appendix S1. The distribution of the interference showed that HLA-C was less affected than HLA-B and -A (P < .0001), the A locus being more frequently represented in the category of falsely negative beads (MFI < 500, P = .0003). The amplitude of the interference Complement interference was defined according to the results from the routine positive control sera used during the course of this study (see Section 2). also differed depending on the locus, HLA-A beads displaying higher MFI differences between treated vs untreated condition than HLA-B beads, followed by HLA-C beads. The same analyses were performed for the 39 sera showing interference in the class II cohort. The median number of affected beads per serum was 5 (minimum 1, maximum 33, first quartile 3 and third quartile 11). Among them, 11 (28.2%) suffered interference on HLA-DR beads, 33 (84.6%) on HLA-DQ and 4 (10.3%) on HLA-DP. A total of 8 sera (20.5% of the sera displaying complement interference and 9.4% of the total number of sera) had at least one antibody specificity with MFI < 500, and as such found absent. The distribution and amplitude of the interference for each class II locus are shown in Table 2 , Figure 2B and SDC, Figure S1B in Appendix S1, and for the class II alleles in SDC, Table S2 in Appendix S1. The distribution of the interference showed that HLA-DQ was largely predominant in comparison with HLA-DR and -DP (P < .0001). For five sera with interference targeting DQ, the DQ-α chain was involved. An example is shown in SDC, Table S3 in Appendix S1. The amplitude of the interference also differed depending on the locus, HLA-DQ beads displaying higher MFI differences between treated vs untreated condition than HLA-DR and -DP beads. The overall amplitude of the interference was not different between the two HLA classes (P = .71).
| Impact of EDTA treatment on weak anti-HLA antibodies
To determine whether EDTA treatment of serum would alter the detection of the authentically weak anti-HLA antibodies, that is, antibodies that were already measured at their true strength in the absence of EDTA, we separately analyzed with Bland-Altman plots all the beads displaying a MFI ≥ 500 with one of the two assays and which were not identified as subject to complement interference ( Figure 3) . A total of 5181 and 2231 beads could be analyzed for class I and for class II respectively. For class I, 4759 (91.9%) beads were positive with both assays, and 290 (5.6%) and 132 (2.5%) were positive only in the absence or presence of EDTA, respectively. For class II, 1875 (84.0%) beads were positive with both assays, and 204 (9.1%) and 152 (6.8%) were positive only in the absence or presence of EDTA respectively. The mean (AESD) absolute MFI difference was 264 AE 1096 and 12 AE 1251 for class I and class II, respectively. To increase stringency, we isolated the subgroup of beads with MFI < 3000 without EDTA (Figure 3) . A total of 2392 and 1231 beads were analyzed in class I and in class II respectively, providing a mean (AESD) absolute MFI difference of 119 AE 390 and 43 AE 520, respectively. We further studied MFI differences around common cut-offs used in clinical interpretation of SAFB results, that is, 500 and 1000 MFI. After pooling class I and class II, 858 beads had a MFI between 400 and 600 without EDTA and the mean (AESD) absolute MFI difference was 39 AE 246. For 405 beads having a MFI between 900 and 1100 MFI without EDTA, the mean (AESD) absolute MFI difference was 115 AE 349.
| DISCUSSION
In this study, we first showed that complement interference was quite frequent, as it occurred for at least one SAFB in 29.5% of patients in class I, and in 45.9% in class II. Therefore, the complement interference is far from being a rare event and, as such, needs to be adequately managed for clinical protocols. Tambur et al. reported a much higher prevalence of the "prozone" inhibition, reaching 71%. 15 Such a high percentage is certainly explained by the inclusion criteria, that limited the recruitment to sera drawn for a clinical indication and with at least one strong antibody (MFI >10 000) detected in neat assay. Therefore this study We also attempted to determine if any characteristics of untreated sera could serve as clues for anticipating complement interference occurrence and then pre-treat on purpose the serum with EDTA, allowing the extra-cost of retrospectively retesting suspicious sera to be avoided. However, for a given serum, neither the number of positive beads nor the highest bead MFI were satisfactory indicators as they provided low sensitivities and/or low specificities. The percentage of sera to be retested when applying these thresholds was estimated to exceed 50% (data not shown). These results strongly claim for a systematic treatment of all sera before performing the assay, given the clinical risk for the patient that accompanies the absence of detection of a complement activating DSA in both the pre-and post-transplant settings.
In parallel, at bead level, we also observed that MFI from untreated serum was a poor predictor of complement interference occurrence in comparison with the treated condition. Interestingly, the optimal EDTA MFI thresholds for predicting complement interference described here are similar to those we recently reported for T-lymphocyte complement-dependent cytotoxicity crossmatch results prediction, 16 but also to those we and others described for C1q-and C3d-binding ability. [17] [18] [19] [20] These concordant findings emphasize the tight link that associates the ability of HLA antibodies to strongly activate the complement and the interference phenomenon. The analysis of the distribution of the interference among the different HLA alleles and its amplitude highlighted a huge heterogeneity. Indeed, for class I, HLA-C was less affected than HLA-A and -B. It could be because recipients mount weaker humoral responses against HLA-C molecules. 21, 22 Also, the density of denatured HLA-C molecules on SAFB surface might be higher than for HLA-A and -B alleles. This could lead to a decrease, by a dilution effect, of the density of the target epitopes for both categories of native and denatured antigens, and then could diminish the intrinsic ability to trigger C1q binding by the anti-denatured or native antibodies. 3, 23, 24 For class II, anti-HLA-DQ dominated the landscape far ahead anti-DR and -DP antibodies, as described previously. 15 It could be due to the fact that recipients mount stronger humoral responses against HLA-DQ molecules and this is of major importance, as anti-DQ antibodies are by far the most frequent DSA produced de novo, from 50% to 80% depending on the transplanted organ. [25] [26] [27] [28] [29] [30] Interestingly, several of these anti-DQ antibodies generating the interference were directed against the DQ-α chain. Noteworthy, we estimated that in about 3% of sera in class I and 9% in class II at least one antibody specificity was missed, having a MFI incorrectly measured below 500, which is of major concern in organ allocation programs. This first leads to biasing patient ranking in waitlists according to the sensitization breadth, and secondly, apart from this extreme situation of the false negative results, underestimating the MFI of still positive specificities can severely impair the virtual crossmatch procedures when transplanting highly sensitized recipients over a supposedly acceptable immunological risk.
All these points underline the importance of systematically removing this interference by serum treatment in routine follow up protocols. However, to be safely implemented in the routine, it was mandatory that this procedure did not modify the MFI values that did not reach the FIGURE 3 Impact of EDTA treatment on weak HLA antibodies. The MFI of all the beads positive with or without EDTA and not identified as suffering complement interference were analyzed with Bland-Altman plots. The analysis was repeated for beads with a MFI < 3000 without EDTA. Full line represents the mean of differences and dashed lines correspond to the mean AE 1.96 SD. EDTA, ethylenediaminetetraacetic acid; MFI, mean fluorescence intensity statistical MFI threshold of complement interference. We indeed showed that EDTA-treatment was innocuous when complement interference was not acting. Especially this remained true for the weak antibodies having MFI centered near the clinical decision thresholds.
In conclusion, by analyzing the effect of EDTA on large cohorts of sera from class I and II HLA sensitized patients, our study emphasized the importance and the advantages of a systematic EDTA pre-treatment of all sera before SAFB assays. Other procedures such as DTT-or heat-treatment are being used, yet a small amount of data has been published about them so far. 8, [31] [32] [33] Noteworthy, while the EDTA-treatment has been described as superior to DTTtreatment for overcoming complement interference, 31, 33 it only partially removes IgM interference, 11 which could nevertheless be less frequent. Heating the serum presents the advantages to not require any chemicals and to avoid any serum dilution. However, it is time consuming and protein denaturation could increase the background for some sera. Interestingly, a very recent article showed that MFI obtained from sera treated with EDTA and heat inactivation are nearly identical, yet the number of sera studied was limited. 33 It would be interesting that laboratories using heat treatment apply similar studies on large cohorts in order to ascertain that the transplant community selects the most efficient and safe procedure.
